CD8A and Miyoshi myopathy: Patient 10, despite having a favorable CD8+ T cell percentage, had a high proportion of myeloid cells, likely including suppressive tumor‐associated macrophages, which may have contributed to a diminished response (Figure S14, Supporting Information).[33] Overall, MATCH treatment significantly reduced MM cell percentages compared to untreated controls in 13 out of 16 patients, underscoring its potential for effective MM targeting (Figure 7E).